UNCY: Unicycive Therapeutics, Inc. Stock

by  •  • Comments Off on UNCY: Unicycive Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 62.28
Enterprise Value ($M) 29.93
Book Value ($M) 27.85
Book Value / Share 0.27
Price / Book 2.24
NCAV ($M) 27.02
NCAV / Share 0.26
Price / NCAV 2.31

Profitability (mra)
Return on Invested Capital (ROIC) -0.80
Return on Assets (ROA) -1.62
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 3.61
Current Ratio 3.61

Balance Sheet (mrq) ($M)
Current Assets 37.74
Assets 38.57
Liabilities 10.72
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
12-20 13G/A Nantahala Capital Management, LLC
12-20 13G/A Nantahala Capital Partners Limited Partnership
11-14 13G/A Vivo Opportunity Fund Holdings, L.P. 9.99 1.67
11-14 13G/A Logos Global Management LP 4.90 46.37
11-14 13G/A Ra Capital Management, L.p. 9.99 201.61
11-14 13G/A Biotechnology Value Fund L P 9.99 201.74
11-14 13G/A Great Point Partners Llc 9.99 11.26
11-13 13G Walleye Capital LLC 5.30
10-11 13G Octagon Capital Advisors LP 9.10
02-14 13G/A Armistice Capital, Llc 2.73 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 221,240 764,680 28.93
2025-02-03 337,163 1,095,005 30.79
2025-01-31 516,162 1,386,973 37.21
2025-01-30 356,084 1,020,880 34.88

(click for more detail)

Similar Companies
TPST – Tempest Therapeutics, Inc. TRAW – Traws Pharma, Inc.
TTNP – Titan Pharmaceuticals, Inc. UPC – Universe Pharmaceuticals INC
UPXI – Upexi, Inc.


Financial data and stock pages provided by
Fintel.io